SpyGlass Pharma, Inc.
SGP
$26.20
$1.034.09%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 60.55% | 15.95% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 42.56% | 13.07% | |||
| Operating Income | -42.56% | -13.07% | |||
| Income Before Tax | -43.75% | -10.06% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -43.75% | -10.06% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -43.75% | -10.06% | |||
| EBIT | -42.56% | -13.07% | |||
| EBITDA | -43.30% | -12.53% | |||
| EPS Basic | 14.34% | 87.88% | |||
| Normalized Basic EPS | 14.33% | 87.88% | |||
| EPS Diluted | 14.34% | 87.89% | |||
| Normalized Diluted EPS | 14.33% | 87.88% | |||
| Average Basic Shares Outstanding | 67.80% | 807.79% | |||
| Average Diluted Shares Outstanding | 67.80% | 807.79% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||